Innovation

What’s Next for Transcatheter Tricuspid Valve Interventions – Technology and Clinical Research

Con: Heterotopic TTVR Indications Are Limited and Should Be Considered as a Last Resort!

Pro: Heterotopic TTVR Technologies Are Evolving, thus Their Indications Will Expand!

MonarQ System for Transcatheter Tricuspid Valve Replacement: Multicenter, First-in-Human Results

Percutaneous Treatment of Tricuspid Regurgitation With the Novel TriFlO® Device: First in Human Italian Experience

Long-Term Follow Up With the DUO Coaptation Valve System for the Percutaneous Treatment of Tricuspid Regurgitation: The TANDEM I Trial

EFS of the Edwards SAPIEN 3 THV System With the Edwards Caval Pre-Stent for the Treatment of Reverse Caval Flow in Patients With Severe TR

Heterotopic TTVR in Patients With Severe TR: First-in-Human Experience With the Trillium Device

TricValve: Technology and Clinical Update

Keynote Lecture: Heterotopic TTVR: Where Do We Draw the Line in Patient Indication?

Early Feasibility Study of the Laplace TTVR System in Patients With Severe, Symptomatic Tricuspid Regurgitation

The Trisol Medical TTVR System: US Experience

The Topaz TTVR System: Technology for Expanded Patient Access and EFS Update

Orthotopic Transcatheter Tricuspid Valve Replacement: LuX-Valve Plus

Orthotopic Transcatheter Tricuspid Valve Replacement: CardioValve

Orthotopic Transcatheter Tricuspid Valve Replacement: Intrepid

Keynote Lecture: Impact of TTVR on Hemodynamics and Ventricular Performance: Are New Generation Technologies Addressing the Physiologic Needs?

New Structural Innovation: What Is Next in the Pipeline From China

Six-Month Outcomes of the LuX-Valve Plus Transjugular Tricuspid Valve Replacement System: A Multicenter Clinical Study in High-Risk Surgical Patients

12-Month Clinical Outcomes of K-Clip® System Transcatheter Tricuspid Annuloplasty Multicenter Pivotal Trial